PMID- 17361314
OWN - NLM
STAT- MEDLINE
DCOM- 20070409
LR  - 20131121
IS  - 1201-5989 (Print)
IS  - 1201-5989 (Linking)
VI  - 12
IP  - 1
DP  - 2007 Feb
TI  - IVIG for the treatment of toxic epidermal necrolysis.
PG  - 7-9
AB  - Intravenous immunoglobulin (IVIG) has been proposed as a treatment for toxic 
      epidermal necrolysis (TEN) and Stevens-Johnson Syndrome (SJS). A number of 
      retrospective and prospective studies have been conducted, with varying levels of 
      evidence for the efficacy of IVIG. Recent publications provide opposing 
      conclusions. A multi-center, comparative, long-term analysis needs to be 
      conducted to determine the role of IVIG in the management of patients with 
      SJS/TEN.
FAU - Mittmann, N
AU  - Mittmann N
AD  - Division of Clinical Pharmacology, University of Toronto, Ontario, Canada.
FAU - Chan, B C
AU  - Chan BC
FAU - Knowles, S
AU  - Knowles S
FAU - Shear, N H
AU  - Shear NH
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Canada
TA  - Skin Therapy Lett
JT  - Skin therapy letter
JID - 9891441
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Stevens-Johnson Syndrome/*drug therapy
RF  - 35
EDAT- 2007/03/16 09:00
MHDA- 2007/04/10 09:00
CRDT- 2007/03/16 09:00
PHST- 2007/03/16 09:00 [pubmed]
PHST- 2007/04/10 09:00 [medline]
PHST- 2007/03/16 09:00 [entrez]
AID - Intravenous immunoglobulin, IVIG, toxic epidermal necrolysis, TEN, 
      Stevens-Johnson Syndrome, SJS [pii]
PST - ppublish
SO  - Skin Therapy Lett. 2007 Feb;12(1):7-9.